Research progress of anti-integrin αvβ6 autoantibody in ulcerative colitis
10.3760/cma.j.cn101480-20250414-00057
- VernacularTitle:抗整合素αvβ6自身抗体在溃疡性结肠炎中的研究进展
- Author:
Menghua FAN
1
;
Ailing LIU
1
;
Yueyuan WANG
1
;
Hao ZHANG
1
;
Xueli DING
1
Author Information
1. 青岛大学附属医院消化内科，青岛 266003
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Anti-integrin αvβ6 autoantibody;
Biomarker;
Diagnosis;
Evaluation
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(4):351-357
- CountryChina
- Language:Chinese
-
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology, primarily involving the colon and rectum. Characterized by recurrent episodes and prolonged disease course, UC requires dynamic monitoring and evaluation. Current commonly used methods for disease monitoring and assessment include C-reactive protein (CRP), fecal calprotectin (FC), and colonoscopy. However, CRP lacks specificity, FC fails to effectively differentiate UC from Crohn's disease, while colonoscopy involves complex bowel preparation, is invasive, and suffers from poor patient compliance. Therefore, there is an urgent clinical need to identify non-invasive biological markers with high sensitivity and specificity for the diagnosis and evaluation of UC. Recent studies have demonstrated that anti-integrin αvβ6 autoantibodies hold significant value in the diagnosis, differential diagnosis, and disease assessment of UC, potentially emerging as an important clinical biomarker. This article reviews the research progress of anti-integrin αvβ6 autoantibodies in UC for reference.
